
Research ReportBNTX
BioNTech (BNTX): Oncology Pipeline Upside vs. Earnings Drag
BioNTech is transitioning from COVID vaccine revenue to a late-stage oncology pipeline, with strong clinical signals but continued earnings pressure. The balance sheet gives it time, but execution risk remains high.
Nov 18, 202622 MIN
